WO2024156884A1 - Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) - Google Patents
Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) Download PDFInfo
- Publication number
- WO2024156884A1 WO2024156884A1 PCT/EP2024/051935 EP2024051935W WO2024156884A1 WO 2024156884 A1 WO2024156884 A1 WO 2024156884A1 EP 2024051935 W EP2024051935 W EP 2024051935W WO 2024156884 A1 WO2024156884 A1 WO 2024156884A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glp
- analogue
- treatment
- patient
- peptide
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 160
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 title claims abstract description 101
- 206010049416 Short-bowel syndrome Diseases 0.000 title claims abstract description 75
- DOAUQKRTILFGHV-PDCMDPCFSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S,3S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]acetyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O DOAUQKRTILFGHV-PDCMDPCFSA-N 0.000 claims abstract description 64
- 229940057954 glepaglutide Drugs 0.000 claims abstract description 61
- 230000009467 reduction Effects 0.000 claims abstract description 37
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims description 98
- 230000003442 weekly effect Effects 0.000 claims description 94
- 238000000034 method Methods 0.000 claims description 56
- 230000004044 response Effects 0.000 claims description 34
- 239000000902 placebo Substances 0.000 claims description 33
- 229940068196 placebo Drugs 0.000 claims description 33
- 230000006872 improvement Effects 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 24
- 230000008859 change Effects 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- 208000037112 Intestinal Failure Diseases 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 239000007929 subcutaneous injection Substances 0.000 claims description 7
- 208000004998 Abdominal Pain Diseases 0.000 claims description 4
- 208000002881 Colic Diseases 0.000 claims description 4
- 230000003872 anastomosis Effects 0.000 claims description 4
- 238000007455 ileostomy Methods 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 description 33
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 32
- 239000000872 buffer Substances 0.000 description 30
- 239000012071 phase Substances 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 21
- 239000012669 liquid formulation Substances 0.000 description 18
- 238000013517 stratification Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 238000007920 subcutaneous administration Methods 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 13
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 12
- 229960002885 histidine Drugs 0.000 description 12
- 235000010355 mannitol Nutrition 0.000 description 12
- 229930195725 Mannitol Natural products 0.000 description 11
- 159000000021 acetate salts Chemical class 0.000 description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 11
- 239000000594 mannitol Substances 0.000 description 11
- 238000005457 optimization Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 210000000813 small intestine Anatomy 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 description 9
- 229960002444 teduglutide Drugs 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 239000008181 tonicity modifier Substances 0.000 description 8
- 230000035622 drinking Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108010073046 teduglutide Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- 206010016803 Fluid overload Diseases 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 208000029632 chronic intestinal failure Diseases 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000006641 stabilisation Effects 0.000 description 6
- 238000011105 stabilization Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- -1 teduglutide Chemical class 0.000 description 5
- 208000005156 Dehydration Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000015626 Glucagon-Like Peptide-2 Receptor Human genes 0.000 description 3
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000003503 early effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 2
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010059017 Intestinal mass Diseases 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000003841 chloride salts Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011867 re-evaluation Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 101500028771 Homo sapiens Glucagon-like peptide 2 Proteins 0.000 description 1
- 101000632994 Homo sapiens Somatostatin Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000035554 Proglucagon Human genes 0.000 description 1
- 108010058003 Proglucagon Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 108700023633 apraglutide Proteins 0.000 description 1
- 229940007438 apraglutide Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000003626 gastrointestinal polypeptide Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Glucagon-like-peptide-2 (GLP-2) analogues and their medical uses the treatment of short bowel syndrome (SBS) are disclosed, in particular medical uses of glepaglutide identied in the EASE SBS 1 trial demonstrating improved patient Quality of Life (QoL) and/or an early reduction in the parenteral support (PS) required by patients as their treatment with glepaglutide progressed.
Description
GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES AND THEIR MEDICAL USES FOR THE TREATMENT OF SHORT BOWEL SYNDROME (SBS)
Field of the Invention
The present invention relates to glucagon-like-peptide-2 (GLP-2) analogues and their medical uses for the treatment of short bowel syndrome (SBS), and in particular to the treatments using glepaglutide that result in improved Quality of Life (QoL) of patients and/or an early or signficant reduction in the parenteral support (PS) required by patients undergoing GLP-2 therapy.
Background of the Invention
Human GLP-2 is a 33-amino-acid peptide with the following sequence: Hy-His-Ala-Asp- Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-lle-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-lle- Asn-Trp-Leu-lle-GIn-Thr-Lys-lle-Thr-Asp-OH. It is derived from specific post-translational processing of proglucagon in the enteroendocrine L cells of the intestine and in specific regions of the brainstem. GLP-2 binds to a single G-protein-coupled receptor belonging to the class II glucagon secretin family.
GLP-2 has been reported to induce significant growth of the small intestinal mucosal epithelium via the stimulation of stem cell proliferation in the crypts, and by inhibition of apoptosis in the villi (Drucker et al., 1996, Proc. Natl. Acad. Sci. USA 93: 7911-7916). GLP-2 also has growth effects on the colon. Furthermore, GLP-2 inhibits gastric emptying and gastric acid secretion (Wojdemann et al., 1999, J. Clin. Endocrinol. Metab. 84: 2513-2517), enhances intestinal barrier function (Benjamin et al., 2000, Gut 47: 112- 119), stimulates intestinal hexose transport via the upregulation of glucose transporters (Cheeseman, 1997, Am. J. Physiol. R1965-71), and increases intestinal blood flow (Guan et al., 2003, Gastroenterology, 125: 136-147).
It has been recognised in the art that glucagon-like peptide-2 receptor analogues have therapeutic potential for the treatment of intestinal diseases. However, the native hGLP- 2, a 33 amino acid gastrointestinal peptide, is not a useful in a clinical setting due to its very short half-life in humans of around 7 minutes for full length GLP-2 [1-33] and 27 minutes for truncated GLP-2 [3-33], In large part, the short half-life is due to degradation by the enzyme dipeptidylpeptidase IV (DPP-IV). Accordingly, there have been attempts in the art to develop GLP-2 receptor agonists with better pharmacokinetic characteristics, in particular to improve the half-life of GLP-2 molecules. By way of example, GLP-2
analogues with substitutions have been suggested such as e.g. GLP-2 analogues containing Gly substitution at position 2 ([hGly2] GLP-2, teduglutide) which increases the half-life from seven minutes (native GLP-2) to about two hours. Teduglutide is approved for the treatment of short bowel syndrome under the name Gattex (in the United States) and Revestive (in Europe).
WO 2006/117565 (Zealand Pharma A/S) describes GLP-2 analogues which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g. as assessed in in vitro stability assays. Among the molecules disclosed in WO 2006/117565 is ZP1848 (glepaglutide) which has been designed to be stable in liquid formulations. Dosage regimes for GLP-2 analogues including ZP1848 and its metabolites are described in WO 2018/229252, which also shows that these compounds are effective to increase longitudinal growth of the intestines. Ready-to use formulations of ZP1848 are described in WO 2020/065064.
Summary of the Invention
Broadly, the present invention is based on the surprising findings arising from the EASE SBS 1 trial, which is a multi-center, placebo-controlled, randomized, parallel-group, double-blind phase 3 clinical trial (NCT:03690206) that looked at the safety and effectiveness of treatment for short bowel syndrome (SBS) using glepaglutide, in particular in relation to end points of the trial relating to patient Quality of Life (QoL) and/or the parenteral support (PS) required by patients as their treatment with glepaglutide progressed. The parameters associated with changes in the PS required by patients include (a) the early occurrence of a significant improvement in reduction in PS volume compared to baseline and (b) the time to a clinical response as defined by the time to a reduction in PS volume of at least 20% compared to baseline.
The results of this EASE SBS 1 trial included the surprising finding that a secondary end point of the trial using Patient Global Impression of Change (PGIC), a PRO (patientreport outcome) tool, where patients rate their change in overall status since start of the trial on a 7-point Likert scale (see https://www.fda.gov/media/116277/download and https://www.fda.gov/media/116281/download), led to improvement and significant differences relative to placebo for both glepaglutide when administered twice weekly (TW) and once weekly (OW) when PGIC was assessed at week 24.
Furthermore, the EASE SBS 1 trial found that there was a significant reduction of PS
volume after 12 weeks, a secondary end point of the trial, in particular for patients treated in the twice weekly (TW) arm of the trial. This early effect is faster than the effect of alternative therapies using GLP-2 analogues, such as teduglutide, and is faster than previously reported patient response to treatment with glepaglutide that demonstrated a reduction in PS volume after 20-24 weeks. The early effect is further supported by the significantly faster time to clinical response with glepaglutide TW compared with placebo.
Without wishing to be bound by any particular theory, the present inventors believe that the rapid reduction in the PS volume required by patients may be linked to the response felt by the patients, for example as represented by improvements in PGIC, possibly with a lag time between the reduction in PS volume and the benefit experienced by the patients.
In the trial, the patients received 10 mg of glepaglutide in both the twice weekly (TW) and once weekly (OW) arms of the trial.
Accordingly, in a first aspect, the present invention provides a glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment of a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the GLP-2 analogue is represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, the method comprises administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time, wherein the treatment results in an improvement in quality of life (QoL) of the patient.
In a further aspect, the present invention provides the use of a glucagon-like peptide 2 (GLP-2) analogue in the preparation of a medicament for the treatment of a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the GLP-2 analogue is represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, the use comprises administering the GLP- 2 analogue to the patient once weekly or twice weekly for a period of time, wherein the
treatment results in an improvement in quality of life (QoL) of the patient.
In a further aspect, the present invention provides a provides a method for treating a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), the method comprising administering to the patient a glucagon-like peptide 2 (GLP-2) analogue represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, wherein administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time results in an improvement in quality of life (QoL) of the patient.
In these aspects of the invention, the improvement in quality of life (QoL) of the patient is assessed using a Patient Global Impression of Change (PGIC) status, for example using a 7-point Likert Scale with responding patients reporting a much improved or very much improved status as compared to treatment with placebo. In some cases, the improved PGIC status of the patient is observable at week 24 of the treatment.
In a further aspect, the present invention provides a glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment of a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the GLP-2 analogue is represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, the method comprises administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time, wherein the treatment leads to a reduction in PS volume at 12 weeks from the start of treatment with the GLP-2 analogue.
In a further aspect, the present invention provides the use of glucagon-like peptide 2 (GLP-2) analogue in the preparation of a medicament for the treatment of a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the method comprises administering to the patient a GLP-2 analogue represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, the method comprises administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time, wherein the treatment leads to a reduction in PS volume at 12 weeks from the start of treatment with the GLP-2 analogue.
In a further aspect, the present invention provides a method for treating a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the method comprises administering to the patent a GLP-2 analogue is represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, wherein administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time leads to a reduction in PS volume at 12 weeks from the start of treatment with the GLP-2 analogue.
By way of example, in the present invention, the treatment may lead to a significant and earlier reduction in PS volume of -2.42 placebo at 12 weeks from the start of treatment with the GLP-2 analogue.
In a further aspect, the present invention provides a glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment of a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the GLP-2 analogue is represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, the method comprises administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time, wherein the treatment leads to an early onset of effect, with a median time to clinical response as defined by a reduction in PS volume of at least 20% of 55 days or 8 weeks for treatment twice weekly with 10 mg glepaglutide and 161 days or 23 weeks for treatment once weekly with 10 mg glepaglutide.
In a further aspect, the present invention provides the use of a glucagon-like peptide 2 (GLP-2) analogue in the prearation of a medicament for the treatment of a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the GLP-2 analogue is represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, the method comprises administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time, wherein the treatment leads to an early onset of effect, with a median time to clinical response as defined by a reduction in PS volume of at least 20% of 55 days or 8 weeks for treatment twice weekly with 10 mg glepaglutide and 161 days or 23 weeks for treatment once weekly with 10 mg glepaglutide.
In a further aspect, the present invention provides a method for treating a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the method comprises administering to the patient a GLP-2 analogue is represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, wherein administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time leads to an early onset of effect, with a median time to clinical response as defined by a reduction in PS volume of at least 20% of 55 days or 8 weeks for treatment twice weekly with 10 mg glepaglutide and 161 days or 23 weeks for treatment once weekly with 10 mg glepaglutide.
In these aspects of the invention, the improvement in quality of life (QoL) of the patient is assessed using a Patient Global Impression of Change (PGIC) status, for example using a 7-point Likert Scale with responding patients reporting a much improved or very much improved status as compared to treatment with placebo. In some cases, the improved PGIC status of the patient is observable at week 24 of the treatment.
The results discosed herein also show that in some patients the treatment with the GLP- 2 analogue enables parenteral support to be completely withdrawn, for example such
that the patient does not require parenteral support after 24 weeks of the treatment. This is also referred to a patient achieving oral or enteral autonomy.
In the present context, the term "parenteral support" or "PS" includes the provision of nutrients and/or fluids to the subject receiving GLP-2 therapy as a means of providing the subject with the nutrients and/or fluids that they require, but are unable to absorb fully due to their condition.
In the present context, the terms achieving "oral or enteral autonomy" refers to patients who had been receiving PS and GLP-2 therapy to improve their gastrointestinal function to the extent that all PS is withdrawn (i.e., PS ceases to be a part of their treatment regimen).
The terms "subject" and "patient" are used interchangeably in this specification. It will be understood that the subject (or patient) is a mammal, and typically a human.
ZP1848 is also effective in increasing intestinal mass and longitudinal intestinal growth, particularly in the small intestine.
The ZP1848 or pharmaceutically acceptable salt will typically be provided as a pharmaceutical composition, comprising ZP1848 or said salt in combination with a pharmaceutically acceptable carrier or excipient.
The individual doses may be for administration via a dosing regime as described elsewhere in this specification.
WO 2018/229252 describes that ZP1848 has an unexpectedly long half-life which may enable alternative regimes, such as once or twice weekly administration, especially when delivered by subcutaneous injection. These results arose from a Phase 2 clinical study in humans using ZP1848 that found that the terminal plasma half-life of the molecule is in fact between 5 and 17 days. The terminal plasma half-life is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium. Without wishing to be bound by theory, it is believed that the half-life of ZP1848 may be due to the combination of the formation of a subcutaneous depot and the formation of metabolites which are slowly released from the subcutaneous depot and which are also agonistic on the GLP-2 receptor. The subcutaneous depot may be formed on administration through
a reaction between the lysine tail of ZP1848 and hyaluronic acid in the subcutaneous compartment.
Thus the once weeky or twice weekly dosing regime may comprise a plurality or course of doses separated in time by 2 days, 2.5 days, 3 days, 3.5 days, 4 days, 5 days, 6 days or 7 days. As will be appreciated in the art, the time between doses may be varied to some extent so that each and every doses is not separated by precisely the same time. This will often be directed under the discretion of the physician separated in time by a clinically acceptable range of times.
In some cases, it may be desirable to divide a total dose into a plurality (e.g. two or three) separate doses or administrations, for example for administration at spaced apart injection sites, for example spacing the injection sites at least 5 cm apart. Such spatially separate administrations will typically be provided at substantially the same time, e.g. on the same day, within one hour of each other, or even closer in time.
In the present context, the term “parental support" or "PS" includes the provision of nutrients and/or fluids to the subject receiving GLP-2 therapy as a means of providing the subject with the nutrients and/or fluids that they require, but are unable to absorb fully due to their condition. The detemination of the correct amount or volume of PS to provide to subjects with SBS who are receiving GLP-2 therapy is a challenge because if PS volume is not adjusted in a timely and appropriate way, patients may experience fluid overload, are at risk of dehydration and may not achieve optimal clinical responses to the therapy. This is further complicated as the PS volume required by a subject will typically vary during the course of GLP-2 therapy depending on their response to the therapy. Typically, the assessment of the amount of PS volume required by the subject as GLP-2 therapy progresses is dependent on how long the therapy has continued and the responsiveness of individual patients to it. In view of this variation, an initial assessment of PS volume may be carried out within the first few days of GLP-2 therapy, and is typically then followed by a weekly assessment during the first month, a monthly assessment over the next 1-3 months, and thereafter an assessment every 3-6 months until the treatment is concluded. This is important as subjects may experience a rapid initial response to GLP-2 therapy, as shown in the examples below, improving the function of the small intestine, for example even before any increase in the length of the intestine is observed. This in turn enables the PS volume to be reduced, thereby avoiding the risk of side effects, such as fluid overload.
Accordingly, in the medical uses disclosed herein, as a subject's need for PS reduces the method or uses may include the step of (a) determining the volume of PS required by the subject at that point in the treatment, (b) comparing it to a baseline PS volume determined at the start of therapy with the GLP-2 analogue and (c) reducing the frequency or volume of the PS where the subject demonstrates improved function of the intestine, such as the small intestine. Optionally, the reduction of a frequency or volume of the parenteral support (PS) can be performed using the algorithm described in the examples.
By way of illustration of the relationship between the amount of parenteral support required by patients and the degree of improvement in intestinal function, it is presently believed that a 40% increase in length and width of the small intestine would result in at least a further 10% improvement in function or absorptive capacity of the small intestine. Generally, the GLP-2 therapy according to the present invention leads to improved function or absorptive capacity of the small intestine of at least 10%, more preferably at least 20%, more preferably at least 30% more preferably at least 40%, and most preferably at least 50%. Additionally or alternatively, the amount of the reduction of parenteral support over the course of GLP-2 therapy is at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40% and most preferably at least 50%. In a preferred embodiment, the reduction of parenteral support is at least 20%.
In a further related aspect, the present invention addresses one of the challenges facing patients and physicians when initiating GLP-2 therapy, namely the appropriate and individualized adjustment in volume of parenteral support (PS) provided to the patient. This is important because if the PS volume is not adjusted in a timely and appropriate way, patients may experience fluid overload, risks of dehydration and may not achieve optimal clinical responses with the therapy.
For example, in a previous 24-week treatment study (see Center for Drug and Evaluation and Research, application number 203441 Grig 1s000, page 16) with the GLP-2 analogue teduglutide, an attempt to reduce the parental nutrition volume by 10% was done at the earliest at week 4, 8, 12, 16, and 20 after start of treatment, if the urine output increased by at least 10% from baseline. Many of the patients in this study suffered from fluid overload and stopped drinking (Jeppesen et al. 2011 , Gut 2011 ;60:902-914). In a follow-
up study, a 24-week study of patients with SBS-IF who were given subcutaneous teduglutide (Jeppesen et al. 2012, Gastroenterology 2012;143:1473-1481), the reduction of parental nutrition to at least 10%, but not more than 30%, was recommended every week if the urine output increases by at least 10% from baseline. However, in this study, the patients also suffered from fluid overload, in particular at the beginning of the treatment.
Consequently, as carried out in the EASE SBS 1 trial described in the example, the present invention enables early assessment of altered PS fluid needs (for example, within a few days of initiating GLP-2 therapy) and provides algorithms for adjusting of PS volume during a course of GLP-2 therapy, in the trial achieving an early onset of clinical response (i.e. > 20% reduction in PS volume) and a significant reduction in PS after 12 weeks. By way of example, an early onset of effect was achieved, with median time to clinical response (reduction in PS volume of at least 20%) of 55 days or 8 weeks for treatment twice weekly with 10 mg glepaglutide and 161 days or 23 weeks for treatment once weekly with 10 mg glepaglutide. It will be appreciated by those skilled in the art that this approach using the algorithm to adjust the PS volume provides a personalised adjustment of the PS volume for each patient. This aspect of the present invention is applicable to GLP-2 therapies using the GLP-2 analogues disclosed herein or using GLP-2 analogues known elsewhere in the art, such as teduglutide or apraglutide. Accordingly, the algorithm for adjusting PS volume disclosed in the examples may be used in any aspect of the present invention.
In all aspects of the present invention, the method of administering the glucagon-like peptide 2 (GLP-2) analogue optionally comprises administering a plurality of doses of the GLP-2 analogue to the patient, wherein the doses are separated in time by one week or half a week. In some cases, it may be desirable to divide a total dose into a plurality (e.g. two or three) separate doses, for example for administration at spaced apart injection sites, for example spacing the injection sites at least 5 cm apart.
Preferably, the doses of the GLP-2 analogues used in accordance with the present invention are in the range between 0.5 mg and 25 mg inclusive per patient once or twice weekly, optionally between 1 mg and 20 mg inclusive per patient once or twice weekly, optionally between 1 mg and 10 mg inclusive per patient once or twice weekly, optionally between 2 mg and 7 mg inclusive per patient once or twice weekly, optionally between 5 mg and 7 mg inclusive per patient once or twice weekly, or optionally between 2 mg and
5 mg inclusive per patient once or twice weekly. In one embodiment, the dose of the GLP-2 analogues used in accordance with the present invention is 10 mg inclusive per patient once or twice weekly. In a course of treatment, the doses taken by the patient may either be the same or different in accordance with the instructions from the physician.
Preferably, the glucagon-like peptide 2 (GLP-2) analogue are administered to patients by injection, most typically by subcutaneous injection or intramuscular injection. In some preferred embodiments, the GLP-2 analogue may be administered using an injection pen, which allow patients to self-administer the analogue. In some aspects, administration of the GLP-2 analogue causes formation of a subcutaneous depot from which the GLP-2 analogue, or metabolites thereof, are released. Without wishing to be bound by any particular explanation, the subcutaneous depot may form through the interaction of the GLP-2 analogues administered in accordance with the present invention, in particular where the analogues comprise a lysine tail, through a reaction between the analogues and with hyaluronic acid in the subcutaneous compartment.
Embodiments of the present invention will now be described by way of example and not limitation with reference to the accompanying figures. However, various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure.
“and/or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example “A and/or B” is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein.
Unless context dictates otherwise, the descriptions and definitions of the features set out above are not limited to any particular aspect or embodiment of the invention and apply equally to all aspects and embodiments which are described.
Brief Description of the Figure
Figure 1 depicts the trial design described in the examples. This phase 3 trial was a pivotal, multicenter, placebo-controlled, randomized, parallel-group, double-blind and fixed dose, designed to confirm the efficacy of glepaglutide in reducing the parenteral support (PS) volume in SBS patients and to evaluate the efficacy of glepaglutide on other
efficacy endpoints as well as the safety and tolerability of glepaglutide in patients with SBS. A 3-arm treatment, parallel- group design with a 1 :1:1 randomization scheme (2 active treatment groups [once and twice weekly] and placebo) was chosen to compare the dosing regimen. The clinical trial is registered at clinicaltrials.gov: NCT03690206.
Figure 2 shows the PS volume (L/week) change from Baseline by visit - treatment policy estimand - primary statistical analysis (Ml CR) in a LSmeans plot. Abbreviations: TW: twice weekly; OW: once weekly; N: number of patients in Full Analysis Set; CR: copyreference; Ml: multiple imputation; PS: parenteral support. Notes: MMRM model includes treatment group, visit, stratification factor, treatment-by-visit interaction as factors and Baseline PS volume (L/Week) as covariate. Variance estimation is based on an unstructured covariance matrix within treatment group. Stratification factor: weekly PS volume requirements <12 L/week and >- 12 L/week.
Figure 3 shows PS volume (L/week) change from Baseline by visit - treatment policy estimand - primary statistical analysis (Ml CR) - LSmeans plot, following exclusion of one technical outlier. Abbreviations: TW: twice weekly; OW: once weekly; N: number of patients in Full Analysis Set; CR: copy-reference; Ml: multiple imputation; PS: parenteral support. Notes: MMRM model includes treatment group, visit, stratification factor, treatment-by-visit interaction as factors and Baseline PS volume (L/Week) as covariate. Variance estimation is based on an unstructured covariance matrix within treatment group. Stratification factor: weekly PS volume requirements <12 L/week and >- 12 L/week.
Detailed Description of the Invention
Definitions
Throughout the description and claims the conventional one-letter for natural amino acids are used. All amino acid residues in the compounds described are typically of the L- configuration.
Compounds
ZP1848 is a peptide having the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2 as described e.g. in WO 2006/117565. It will be understood that the N-terminal "H-"
indicates the hydrogen of a free N-terminal amine (NH2 group). The C-terminal "NH2-" indicates a C-terminal amide group. The terms "ZP1848" and "glepaglutide" may be used interchangeably.
The present invention relates to the use of pharmaceutically acceptable salts of ZP1848, as described in more detail below. Any suitable salt may be used, although acetate may be preferred.
When ZP1848 is injected into the subcutaneous (SC) compartment, two functionally active metabolites are formed, ZP2469 and ZP2711, both C-terminal truncated analogs of ZP1848. The overall PK profile of ZP1848 therefore comprises the effect of ZP1848 and its two main metabolites.
ZP2469 is a peptide having the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDK-OH
ZP2711 is a peptide having the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKK-OH where the N-terminal "H-" is as described above, and the C-terminal "-OH" indicates a free C-terminal carboxylic acid group.
Teduglutide is a peptide having the formula:
H-HGDGSFSDEMNTILDNLAARDFINWLIQTKITD-OH where the N-terminal "H-" and C-terminal "-OH" are as described above.
Pharmaceutical Compositions and Administration
The GLP-2 analogue as used herein may be formulated as pharmaceutical compositions prepared for storage or administration, and which comprise a therapeutically effective amount of the GLP-2 analogue in a pharmaceutically acceptable carrier.
Suitable salts include acid addition salts and basic salts. Examples of acid addition salts
include hydrochloride salts, citrate salts, chloride salts and acetate salts. Preferably, the salt is acetate. In general, it is preferred that the salt is not a chloride salt. Examples of basic salts include salts where the cation is selected from alkali metals, such as sodium and potassium, alkaline earth metals, such as calcium, and ammonium ions +N (R3) 3(R4), where R3 and R4 independently designates optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted aryl, or optionally substituted heteroaryl.
Acetate salts may be particularly preferred. In the present context, the term "ZP1848- acetate" refers to the ZP1848 molecule is in the form of an acetate salt. The acetate salts of ZP1848 30 may be represented by the formula (ZP1848), x(CH3COOH) where x is 1.0 to 8.0, i.e. where x is 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0 or 8.0. In any composition, there may be molecules with different number of acetate molecules so that x is not necessarily a whole integer. In some cases, x is from 4.0 to 8.0, x is from 6.0 to 8.0, or x is from 4.0 to 6.5. In some cases, x is from 4.0 to 6.0, x is from 2.0 to 7.0, x is from 3.0 to 6.0, x is from 4.0 to 6.0 or x is 4.0 to 8.0.
When administration is to be parenteral, such as subcutaneous or intramuscular injectable pharmaceutical compositions can be prepared in conventional forms. Glepaglutide is generally provided as aqueous liquid formulations, for example as described in WO 2020/065064 and WO 2020/065063, the contents of which are incorporated by reference in their entirety. Subcutaneous administration may be particularly preferred, e.g. by injection.
The therapeutic dosing and regimen most appropriate for patient treatment will of course vary with the disease or condition to be treated, and according to the patient parameters. Without wishing to be bound by any particular theory, it is expected that doses, between 0.1 and 25 mg per patient, and shorter or longer duration or frequency of treatment may produce therapeutically useful results, such as a statistically significant increase particularly in small bowel mass. In some instances, the therapeutic regimen may include the administration of maintenance doses appropriate for preventing tissue regression that occurs following cessation of initial treatment. The dosage sizes and dosing regimen most appropriate for human use may be guided by the results obtained by the present invention, and may be confirmed in further clinical trials.
A human dose (total dose) of ZP1848 may be from about such as between and including
0.1 mg and 25 mg per patient between and including 0.5 mg and 20 mg per patient, such as between and including 1 mg and 15 mg per patient, such as between and including 1 mg and 10 mg per patient once or twice weekly or as a plurality of doses as defined herein separated in time by 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days. In some instances, a fixed dose of ZP1848 may be used in accordance with a dosing pattern disclosed herein, i.e. a dose which is the same regardless of the body weight of the patient, given once or twice weekly. By way of example, the fixed dose may be a dose of 1.25 mg, 2.5 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9, mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg or 15 mg. Conveniently, a fixed dose of 10 mg may be used as done in the EASE SBS 1 trial reported in the examples. The use of fixed dosing has the advantage of increasing compliance and reducing the risk of patient dosing errors, including risks of miscalculating a weight based dose to be administered.
In preferred embodiments, the formulation is a ready-to-use formulation as described in WO 2020/065064. The term "ready-to-use" as used herein refers to a formulation that does not require constitution or dilution with a prescribed amount of diluent, e.g., water for injection or other suitable diluent, before use by the designated route of administration.
As described herein, the liquid formulations of the GLP-2 analogues of the present invention include a buffer, a non-ionic tonicity modifier and arginine q.s. to provide the pH of the final formulation. In accordance with normal pharmaceutical practice, the formulations of the present invention are sterile and/or free from reducing agent. In preferred cases, the liquid formulations of the present invention are aqueous, liquid formulations. In some cases, the liquid formulations of the present invention are nonaqueous, liquid formulations.
The term "buffer" as used herein denotes a pharmaceutically acceptable excipient which stabilizes the pH of a pharmaceutical formulation. Suitable buffers are well known in the art and can be found in the literature. The screening experiments in the examples show that the formulations of the present invention preferably include a buffer selected from a histidine buffer, mesylate buffer, acetate buffer, glycine buffer, lysine buffer, TRIS buffer, Bis-Tris buffer and MOPS buffer as these buffers provided stable formulations in which the GLP-2 analogues dissolved and did not become viscous, cloudy or precipitate the peptide drug. In preferred embodiments, the buffer is a histidine buffer, e.g. L-histidine. Generally, the buffer will be present at a concentration of about 5 mM to about 50 mM,
more preferably at a concentration of about 5 mM to about 25 mM, and most preferably at a concentration of about 15 mM. Preferably the buffer is not a phosphate buffer, a citrate buffer, citrate/Tris buffer and/or succinate buffer.
The term "tonicity modifier" as used herein denotes pharmaceutically acceptable tonicity agents that are used to modulate the tonicity of the formulation. The formulations of the present invention are preferably isosmotic, that is they have an osmotic pressure that is substantially the same as human blood serum. The tonicity modifiers used in the formulations are preferably non-ionic tonicity modifiers and are preferably selected from the group consisting of mannitol, sucrose, glycerol, sorbitol and trehalose. A preferred non-ionic tonicity modified is mannitol, e.g. D-mannitol. The concentration of the tonicity modifier will be dependent on the concentration of other components of the formulation, especially where the formulation is intended to be isosmotic. Typically, the non-ionic tonicity modifier will be employed at a concentration of about 90 mM to about 360 mM, more preferably at a concentration of about 150 mM to about 250 mM, and most preferably at a concentration of about 230 mM.
Generally, the components and amounts of the liquid formulations are chosen to provide a formulation with a pH of about 6.6 to about 7.4, more preferably a pH of about 6.8 to about 7.2, and most preferably a pH of about 7.0. Arginine may be added quantum sufficit (q.s.) to adjust pH so that it is within a desired pH range. It is preferred that the pH adjustment is not done using hydrochloric acid or sodium hydroxide.
In one embodiment, the liquid formulations consist of ZP1848, e.g. an acetate salt thereof, at a concentration of about 2 mg/ml to about 30 mg/ml a buffer selected from the group consisting of a histidine buffer, mesylate buffer, acetate buffer, glycine buffer, lysine buffer, TRIS buffer, Bis-Tris buffer and MOPS buffer, the buffer being present at a concentration of about 5 mM to about 50 mM, a non-ionic tonicity modifier selected from the group consisting of mannitol, sucrose, glycerol, sorbitol and trehalose at a concentration of about 90 mM to about 360 mM, arginine q.s. to provide a pH of about 6.6 to about 7.4.
In one embodiment, the liquid formulations consist of ZP1848, e.g. an acetate salt thereof, at a concentration of about 2 mg/ml to about 30 mg/ml, a buffer selected from the group consisting of a histidine buffer, mesylate buffer and acetate buffer, the buffer being present at a concentration of about 5 mM to about 50 mM, a non-ionic tonicity
modifier selected from the group consisting of mannitol, sucrose, glycerol and sorbitol at a concentration of about 90 mM to about 360 mM, arginine q.s. to provide a pH of about 6.6 to about 7.4.
In a further preferred embodiment, the liquid formulations comprise ZP1848, e.g. an acetate salt thereof, at a concentration of about 20 mg/ml, histidine buffer at a concentration of about 15 mM, mannitol at a concentration of about 230 mM, and arginine q.s. to provide a pH of about 7.0.
In a further embodiment, the liquid formulations comprise ZP1848, e.g. an acetate salt thereof, at a concentration of about 20 mg/ml, histidine buffer at a concentration of about 15 mM, mannitol at a concentration of about 230 mM and the pH is about 7.0.
In a further embodiment, the liquid formulations comprise ZP1848-acetate or H- HGEGTFSSEIATIIDAIAARDFIAWLIATKITDKKKKKK-NH2 acetate (SEQ ID NO: 1) at a concentration of about 20 mg/ml, histidine buffer at a concentration of about 15 mM, mannitol at a concentration of about 230 mM, and arginine q.s. to provide a pH of about 7.0.
In a further embodiment, the liquid formulations comprise ZP1848-acetate or H- HGEGTFSSEIATIIDAIAARDFIAWLIATKITDKKKKKK-NH2 acetate (SEQ ID NO: 1) at a concentration of about 20 mg/ml, histidine buffer at a concentration of about 15 mM, mannitol at a concentration of about 230 mM and the pH is about 7.0.
The skilled person will appreciate that is cases where a formulation comprises the GLP-2 analogue at a concentration of 20 mg/mL, a patient can be administered a 0.5 ml dose to treat them with 10 mg of the GLP-2 analogue.
In a further embodiment, the liquid formulations comprise an acetate salt of a glucagon- like peptide 2 (GIP-2) analogue having the formula:
(H-HGEGTFSSEIATIIDAIAARDFIAWLIATKITDKKKKKK-NH2), X(CH3COOH) where x is 1.0 to 8.O., at a concentration of about 20 mg/ml, histidine buffer at a concentration of about 15 mM, mannitol at a concentration of about 230 mM and the pH is about 7.0.
In a further embodiment, the liquid formulations comprise an acetate salt of a glucagon- like peptide 2 (GIP-2) analogue having the formula:
(H-HGEGTFSSEIATIIDAIAARDFIAWLIATKITDKKKKKK-NH2), x(CH3COOH) where x is 1.0 to 8.O., at a concentration of about 20 mg/ml, histidine buffer at a concentration of about 15 mM, mannitol at a concentration of about 230 mM and the pH is about 7.0, in a once or twice daily dosing regimen.
In a further embodiment, the liquid formulations comprise an acetate salt of a glucagon- like peptide 2 (GIP-2) analogue having the formula:
(H-HGEGTFSSEIATIIDAIAARDFIAWLIATKITDKKKKKK-NH2), x(CH3COOH) where x is 1.0 to 8.O., at a concentration of about 20 mg/ml, histidine buffer at a concentration of about 15 mM, mannitol at a concentration of about 230 mM and the pH is about 7.0, in a once or twice weekly dosing regimen.
In some cases, the liquid formulations of the present invention further comprise a preservative. In some cases, the preservative is one selected from the group consisting of benzalkonium chloride, chloro butanol, methyl paraben and potassium sorbate. Generally, the preservative is present in a concentration of about 0.1 % to about 1% of the final formulation volume.
Medical Conditions
The peptides of the present invention are useful as a pharmaceutical agent for treating an individual suffering from short-bowel syndrome. Accordingly, ZP1848 or a salt thereof may be useful therapeutically and/or prophylactically for the treatment of short bowel syndrome (SBS), also known as short gut syndrome or simply short gut, which results from surgical resection, congenital defect or disease-associated loss of absorption in the bowel in which patients are subsequently unable to maintain fluid, electrolyte, and nutrient balances on a conventional diet. Despite an adaptation that occurs generally in the two years after resection, SBS patients have reduced dietary uptake and fluid loss.
The class of human patients with SBS includes patients having SBS-intestinal failure (SBS-IF) and patients who are on the border between having SBS-intestinal insufficiency (SBS-II) and SBS-intestinal failure (SBS-IF). In some cases, patients having SBS- intestinal failure (SBS-IF) are also called SBS-PS when they are dependent on parenteral support, and the patients having SBS-intestinal insufficiency (SBS-II) are also called SBS non-PS if they are not depending on parenteral support. In the EASE SBS 1 phase 3 clinical trial reported herein, the patients recruited for the trial to assess the efficiacy and safety (EASE) of glepaglutide had SBS chronic intestinal failure (SBS-CIF). The aim of the trial was to reduce the need for PS and to improve quality of life (QoL).
Patients with SBS may be further categorised in different SBS classes based on their remaining bowel sections and the present invention may be used to treat each of these patient groups for example where the patient has undergone an end-jejunostomy or ileostomy, a jejuna-colic anastomosis or a jejuna-ilea-colic anastomosis.
In the medical uses of the present invention, patients receiving PS may be categorised using at an ESPEN guideline level of any one of A1 , B1 , C1 , D1 , A2, B2, C2, D2, A3, B3, C3, D3, A4, B4, C4, or D4. This categorises patients on the basis of the energy and volume of the required PS, the patients are categorized into combinations (adapted from Pironi L, Arends J, Bozzetti F, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin. Nutr., 35(2): 247-307; 2016 see the Table below).
Clinical classification of Chronic Intestinal Failure (CIF) and the volume of the required intravenous supplementation, CIF is categorized into 16 combinations:
a Calculated as daily mean of the total volume infused per week% (volume per day of infusion x number of infusions per week)/7. b Calculated as daily mean the total energy infused per week% (energy per day of infusion x number of infusions per week)/7/Kg.
The assessment of the volume of PS a patient requires can be determined as set out the the section in the Examples titled "Procedures" and "Treatment Phase". The approach can be used to calculate clinical parameters used in the present invention to define the physiological and pathological responses of classes of patient treated for SBS with glepaglutide. These parameters include (a) the early time where a statistically significant improvement in reduction in PS volume compared to baseline is observed. In the present invention reported to be 12 weeks for treatment TW with 10 mg glepaglutide, which is than that observed in previous studies 20 to 24 weeks previously), and (b) the median time to clinical response as defined by a reduction in PS volume of at least 20% of 55 days or 8 weeks for treatment twice weekly with 10 mg glepaglutide and 161 days or 23 weeks for treatment once weekly with 10 mg glepaglutide.
As set out in the examples, QoL may be assessment using a Patient Global Impresson of Change (PGIC) scale (see https://www.fda.gOv/media/116277/download and https://www.fda.gov/media/116281/download). The PGIC evaluates overall health status as perceived by the patient in a seven-point single-item scale ranging from 'very much worse' to 'very much improved', i.e. yes/no meaning that the patients are responders if they have ticked either "very much improved" or "much improved "in their PGIC questionnaire. The PGIC scale used in the EASE-SBS trial program was a 7-point Likert scale with patients asked to tick one box in response to the question:
Since the start of the trial, my overall status is:
(1) Very Much Improved
(2) Much Improved
(3) Minimally Improved
(4) No Change
(5) Minimally Worse
(6) Much Worse
(7) Very Much Worse
PGIC improvement was defined as patients reporting a “much improved” or “very much improved” on the 7-point Likert Scale for each of the weeks 4, 12, 20, and 24. The difference between each glepaglutide treatment regimen compared to placebo was tested using the CMH test adjusting for the stratification factor.
In the results of the EASE SBS 1 clinical trial reported in the Examples found that
glepaglutide treatment of SBS-CIF patients was safe, well-tolerated and resulted in improvement in clinically and patient-centric meaningful outcomes (PS needs, enteral autonomy, and PRO). The onset of effect was suprisingly early for treatment with GLP-2 with a median time to clinical response of just 8 weeks with TW. There was a significant improvement in the patient reported outcome measure, PGIC, for treatment with glepaglutide both TW and OW. The population of SBS patients is considered very heterogenuous and the finding is surprising with treatment of GLP-2.
The spectrum of patient types with SBS is reviewed in Jeppensen, Journal of Parenteral and Enteral Nutrition, 38(1), 8S-13S, May 2014, doi: 10.1177/0148607114520994. A further division of SBS patient types can be made along the lines described in Schwartz et al., Clinical and Translational Gastroenterology (2016) 7, e142; doi: 10.1038/ctg.2015.69. This separates SBS patients into early responders and late/slow responders. It is presently believed that the early responders are the ones who exhibit an early effect on treatment with a GLP-2 analogue such as ZP1848 caused by, among other effects, an increase in the width/diameter of the small intestine, while the late or slow responders are the patients which mostly or first benefit to the treatment with a GLP-2 analogue caused by an increase in the length of the small intestine. The determination of whether a subject is an early or a late responder may be used to determine the duration of the treatment regime with the GLP-2 analogue, the timing of any clinical decision to reduce parenteral support and the interval between testing to determine whether a reduction in parenteral support is possible. Accordingly, in one embodiment, the patient is a late or slow responder. The length of the small intestines may for example bemeasured by CT scan (computed tomography scan), MRI (magnetic resonance imaging), histology, laparoscopic or other measurements or techniques known in the art.
Further aspects of the invention relate to increasing the intestinal mass or longitudinal growth of the intestines in a patient, e.g. in a human patient, especially the small intestine. ZP1848 or a salt thereof is capable of increasing the longitudinal growth of the intestines relative to a control treatment, as shown in WO 2018/229252.
This capability is of particular value in patients with SBS as this will lead to increased absorptive capacity also after treatment is stopped. Such a patient would be treated for at least 1 to 3 years, such as at least 1 to 4 years, such as 1 to 10 years, such as 1 to 20 years, such as 1 to 35 years with the objective of inducing longitudinal growth of the
intestines.
As already described herein, SBS patients who are on the border between intestinal insufficiency (SBS-II) or SBS-PS patients and intestinal failure (SBS-IF) or SBS non-PS may therefore have particular value from having their intestines lengthened over a 1 to 3 year treatment course, whereafter their risk if intestinal failure is decreased, for example involving weekly or twice weekly dosing over the period of treatment. This involves less risk for central catheter needs and the risk of sepsis associated with its use.
The active agents may also be used for the treatment of malnutrition, for example resulting from cachexia and anorexia.
Examples
The following examples are provided to illustrate preferred aspects of the invention and are not intended to limit the scope of the invention. The GLP-2 analogues administered according to the dosage regimes described herein can be made according to the methods such as solid phase peptide synthesis described in WO 2006/117565 and PCT/EP2022/087440 filed on 22.12.2022, the contents of which are expressly incorporated by reference in its entirety.
Trial design
This was a multinational, placebo-controlled, randomized, parallel-group, double-blind phase 3 trial to demonstrate the superiority of once-weekly (OW) and twice-weekly (TW) subcutaneous (SC) injections of 10 mg glepaglutide versus placebo in stable SBS patients. The trial (clinicaltrials.gov identifier: NCT03690206) was conducted at 29 hospital centers (number of centers in parenthesis) across the US (7), the UK (5), Belgium (1), Canada (3), Denmark (2), France (2), Germany (5), the Netherlands (1), and Poland (3). Patients were randomized 1:1:1 via an interactive web response system (IWRS) to 24 weeks of treatment with either glepaglutide TW, glepaglutide OW, or placebo, with trial drug administered SC in either abdomen or thigh. Randomization was performed using a block randomization scheme stratified by the patient’s weekly PS volume requirement at baseline (< 12 L per week versus > 12 L/week). To maintain the blind, all 3 treatment arms involved twice-weekly dosing (glepaglutide and/or placebo). The primary and key secondary endpoints aimed to confirm the efficacy of glepaglutide in reducing or eliminating the need for parenteral support (PS).
Management of short bowel syndrome (SBS) with intestinal failure (IF) targets clinical patient-centric outcomes including reducing need of parenteral support (PS) and improved quality of life (QoL).
The trial was carried out in accordance with the Declaration of Helsinki, International Conference on Harmonization guidelines, and Good Clinical Practice. An Institutional Review Board or Independent Ethics Committee approved the trial at each center, and all participants gave written informed consent prior to undergoing any trial-related procedures or assessments.
Participants
Key inclusion criteria comprised diagnosis of SBS defined as remaining small bowel in continuity of estimated length of less than 200 cm or 79 inches (Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003;124(4):1111-34. DOI: 10.1053/gast.2003.50139a.); requirement for PS at least 3 days per week; presence of a stoma or a colon in continuity; and age 18-90 years. In addition, a number of exclusion criteria were defined (of which several where rechecked at time of randomization) to ensure the validity of efficacy assessments and to exclude patients with significant comorbidities that could bias the safety evaluation. These included having more than 2 SBS-related or PS-related hospitalizations within 6 months prior to screening; poorly controlled inflammatory bowel disease that was moderately or severely active or fistula interfering with measurements or examinations required in the trial; bowel obstruction; known radiation enteritis or significant villous atrophy; cardiac disease within the last 6 months prior to screening; clinically significant abnormal electrocardiogram; acute or unstable chronic liver disease; history of colon cancer; hepatic impairment; use of GLP-1, GLP-2, dipeptidyl peptidase (DPP)-4 inhibitors, human growth hormone, somatostatin, or analogs thereof, within 3 months prior to screening; and unstable biological therapy within 6 months prior to screening.
Procedures
Following informed consent and initial confirmation of eligibility, patients entered a run-in phase consisting of PS optimization and stabilization phases. This was to ensure a reliable baseline for assessing the efficacy of glepaglutide treatment in reducing PS requirements.
During the optimization phase, the investigator could change the PS volume and content according to institutional standard practice if the patient was considered unstable or not optimized. Prior to each optimization visit, the patient was to measure his/her urine volume over 48 hours while adhering to a predefined 48-hour drinking menu. During this period the patient was to record urine volume and oral fluid intake in an eDiary. The effect of PS optimizations was investigated after 2 weeks. With no more than two rounds of PS optimization being allowed, this limited the optimization phase to a maximum duration of 4 weeks. During the optimization phase, the investigator and the patient was allowed to redefine and optimize the individual drinking menu to best fit the patient’s needs. Once the drinking menu had been set at the end of the optimization phase, the patient was required to adhere to this drinking menu during the 48-hour balance periods throughout the remainder of the trial.
A stabilization phase of 2 to 4 weeks of duration immediately followed the optimization phase (the last optimization phase visit could serve as the first stabilization phase visit). No changes in the prescribed weekly PS volume or schedule were allowed during this phase. Prior to each stabilization phase visit, the patient was to measure his/her urine volume over 48 hours while adhering to the set drinking menu and report the urine volume and oral fluid intake in the eDiary. Stabilization phase visits occurred every 2 weeks until fulfilling the following PS stability criteria that qualified for randomization to investigational product treatment:
• Actual PS usage (volume and content) matched prescribed PS (± 10% deviation in total volume is acceptable), and
• 48-hour urine volumes at 2 consecutive visits within a 2-week interval (± 4 days) were similar (up to ± 25% deviation was considered acceptable), while the oral fluid intake was constant (the two 48-hour oral intakes differed by less than 10%) and not exceeding 3.5 L per day, and
• Urine volume was on average > 1 L per day and < 2.5 L per day.
If stability could not be obtained during the 4-week period due to unforeseen events such as infections, illness or similar, a second stabilization phase of up to 4 weeks was allowed.
During the subsequent 24-week treatment phase, PS requirements were evaluated through the use of 48-hour balance periods pertaining to the 48 hours leading up to the treatment initiation visit as well as leading up to the site visits at weeks 1, 2, 4, 8, 12, 16,
20 and 24 following treatment initiation. The balance periods involved a fixed drinking menu (individually pre-defined during the optimization phase) and measurements of urine volume, based on which the PS volume could be adjusted according to the following predefined algorithm:
• IF: daily urine volume of the current visit is at least 10% higher than baseline urine volume.
• THEN: New PS volume (weekly) = Current PS volume (weekly) - 7 x absolute increase in daily urine volume from baseline.
The volume and type of PS actually used were recorded by the patient on an ongoing basis in an eDiary. In general, patients were to remain well hydrated during the trial. The urine production was to stay above 1 L per day for all patients, in accordance with treatment guidelines (Pironi L, Arends J, Bozzetti F, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr 2016;35(2):247-307. DOI: 10.1016/j.clnu.2016.01.020). Once investigational product treatment had been initiated, PS volume could be adjusted at Weeks 1 , 2, 4, 8, 12, 16, 20, and 24 according to the pre-defined algorithm above. Changes to the content of PS were at the discretion of the investigator, and it was allowed to deviate from the algorithm for PS adjustment if clinical conditions like for instance dehydration or signs of fluid overload were present. The rationale for deviating from the algorithm was to be documented in the eCRF.
Unscheduled visits (preceded by a 48-hour measurement period) could be considered by the investigator to adjust PS.
Other efficacy parameters included body weight and patient-reported outcomes. Safety data were recorded throughout the trial period.
Participant recruitment was closed prematurely due to the continued uncertainty about the global prognosis for COVID-19 in 2022 and the possible consequences for trial conduct and completion. With the resulting final trial population of 106 patients and based only on a priori assumptions, the power to show superiority on the primary endpoint for either once- or twice-weekly glepaglutide relative to placebo was approximately 95%.
Statistical Analysis
For primary endpoint was change in actual weekly PS volume from baseline to Week 24,
regardless of whether or not treatment was discontinued. The primary endpoint analysis applied a restricted maximum likelihood (REML)-based repeated-measures approach to compare treatment groups with respect to the mean change from baseline in actual weekly PS volume at Week 24. The model used actual weekly PS volume assessments at Weeks 1, 2, 4, 8, 12, 16, 20, and 24 (derived as the actual weekly PS volume received during a valid 7-day period) as an independent variable, and included the covariates of treatment group, baseline actual weekly PS volume, visit (categorical variable), stratification factor (weekly PS volume requirements <12 L/week versus >12 L/week), and visit-by-treatment group interaction. Variance estimation was based on an unstructured covariance matrix, which did not assume a particular correlation structure for repeated weekly PS volume measurements within patients over time. The primary comparisons were the contrasts (differences in least squares means) between the glepaglutide treatment groups and the placebo group at the Week 24 visit in this mixed- effects model for repeated measures (MM RM). Missing values were imputed using multiple imputation methods. Of the 4 key secondary endpoints, the 3 responder endpoints were analyzed using the Cochran-Mantel-Haenszel test adjusted for the stratification factor (baseline weekly PS volume requirement <12 L/week versus >12 L/week). Missing values for these endpoints were imputed as no response. For the remaining key secondary endpoint of reduction in weekly PS volume from baseline to Week 12, the difference between each glepaglutide treatment group versus placebo was analyzed using the mixed effects model for repeated measures (MMRM) described for the primary endpoint. A parallel gatekeeping testing procedure (testing hierarchy) was applied to protect the overall type I error rate of a (alpha) when testing the primary and key secondary endpoints across the two glepaglutide treatment groups versus placebo.
Patient Global Impresson of Change (PGIC) Patient-Reported Outcomes (PROs)
The PGIC was used to investigate the effects of treatment on health-related quality of life (HRQoL).
Questionnaires were completed in paper format at site visits prior to any other trial related assessment. The PROs were completed by patients enrolled in the trial without assistance of site personnel. The PROs were completed at home before the patient attended the visit to the clinic. Patients were instructed to complete the PRO in a private area without influence from trial team members or accompanied by family or friends. No one was allowed to answer or interpret items for the patient. The Investigator or a
delegated trial team member was allowed to read items/answers options to the patient aloud if the patient was unable to read. The Investigator or delegated trial team member instructed the patient to complete every item in the PROs and explained that there are no right or wrong answers. The Investigator or a delegated trial team member instructed the patient to give the best answer they can and explained that all individual responses were to remain confidential.
Immediately after completion, the PROs were reviewed by the Investigator (or designee) for completeness and potential adverse events (AEs). When reviewing the PROs for AEs, the Investigator was instructed not to influence nor question the patient on the content of their response to PRO questions. The review of the PROs was documented. If entries were missing in the PROs, the patient was asked to answer all questions, with care taken not to bias the patient.
The Investigator and/or delegated trial team members received training and instruction in completion of the PROs prior to the conduct of the trial.
Patients reported in the eDiary their number of bowel movements/stoma bag emptying during the 48-hour balance periods.
Improvement at Weeks 4, 12, 20, and 24
The PGIC scale used in the EASE-SBS trial program was a 7-point Likert scale with patients asked to tick one box in response to the question:
"Since the start of the trial, my overall status is:
(1) Very Much Improved
(2) Much Improved
(3) Minimally Improved
(4) No Change
(5) Minimally Worse
(6) Much Worse
(7) Very Much Worse"
PGIC improvement was defined as responding “much improved” or “very much improved” on the 7-point Likert Scale for each of the weeks 4, 12, 20, and 24. Improvement between each glepaglutide treatment regimen compared to placebo was tested using the CMH test with stratification on the randomization stratification factor.
Results
106 patients were randomized and 102 completed the trial. Treatment arms were overall well-balanced for patient demographics and baseline characteristics.
Glepaglutide was assessed to be safe and well-tolerated. More adverse events were reported in the glepaglutide treatment groups than for placebo, primarily attributable to mild injection site reactions.
PS Requirements
Glepaglutide TW treatment significantly reduced PS requirements versus placebo (mean change of -5.13 vs. -2.85 L/week; estimated difference of -2.28 L/week [-3.83; -0.73]95% Cl; p=0.0039). Glepaglutide TWwas also superior versus placebo for proportion of patients achieving clinical response (65.7% vs. 38.9%; estimated difference of 26.6% [4.3; 48.9]95% Cl; p=0.0243), and percentage of patients achieving a reduction in days on PS >1 day/week (51.4% vs. 19.4%; estimated difference of 31.7% [11.4; 51 ,9]95% Cl; p=0.0043).
TW treatment showed an early onset of effect, as time to clinical response was significantly shorter compared with placebo (p=0.0043) with median time to response of 55 days [ 29 ; 85]95%CI , as shown by the results reported in Table 1.
Table 1
Notes: (1): Taking interval censoring into account. Reference for Sun test: Sun, J. (1996), A Nonparametric Test for Interval-Censored Failure Time Data with Application to AIDS Studies, Statistics in Medicine, 15, 1387-1395.
TW treatment with glepaglutide led to a significant and earlier improvement in reduction in PS volume at 12 weeks, as shown by the results reported in Table 2 and Figure 2.
Table 2
PS volume (L/week) change from Baseline by visit - treatment policy estimand - primary statistical analysis (Ml CR)
Abbreviations: TW: twice weekly; OW: once weekly; N: number of patients in Full Analysis Set; Cl: confidence interval; CR: copy- reference; Ml: multiple imputation; PS: parenteral support.
Notes: MMRM model includes treatment group, visit, stratification factor, treatment-by-visit interaction as factors and Baseline PS volume (L/Week) as covariate. Variance estimation is
based on an unstructured covariance matrix within treatment group. Stratification factor: weekly PS volume requirements <12 L/week and >=12 L/week.
No statistically significant difference was established for glepaglutide OW versus placebo for these endpoints, but a dose-dependent trend was observed. Of special notice, enteral autonomy was achieved for 5 (14%), 4 (12%) and 0 patients receiving glepaglutide TW, OW and placebo, respectively.
Early onset of effect is seen, with a significantly shorter time to clinical response with TW compared with placebo (p=0.0043), and the finding is further supported with significant reduction in PS need after 12 weeks of treatment with TW (p=0.0019).
In addition, the EASE SBS 1 trial examined the time to clinical response as defined by a reduction in PS volume from baseline (placebo) of at least 20%, a further clinical parameter that defines the nature of the response of SBS patients to treatment with glepaglutide 10mg TW or OW. The results of this analysis are set out in Table 1.
This shows that treatment with glepaglutide leads leads to an early onset of effect, with median time to clinical response (reduction in PS volume of at least 20%) of 55 days or 8 weeks for treatment TWwith 10 mg glepaglutide and 161 days or 23 weeks for treatment OWwith 10 mg glepaglutide.
PGIC Improvement
Improvement in PRO using PGIC was shown with significant differences relative to placebo for both glepaglutide TW (p=0.0020) and OW (p<0.0001) as shown in Tables 3 and 4.
Table 3
Abbreviations: TW: twice weekly; OW: once weekly; N: number of patients in Full Analysis Set; Cl: confidence interval; MMRM model includes treatment group, visit, stratification factor, treatment- by-visit interaction as factors. PGIC: patient global impression of change scale.
Notes: Variance estimation is based on an unstructured covariance matrix within treatment group. Stratification factor: weekly PS volume requirements <12 L/week and >=12 L/week.
Table 4
PGIC overall status (improved yes/no, much/very much improved yes/no) at week 24 - treatment policy estimand (observed data)- statistical analysis (NR)
Abbreviations: TW: twice weekly; OW: once weekly; N: number of patients in Full Analysis Set; Cl: confidence interval; NR: non response imputation; PGIC: patient global impression of change scale.
Notes: The difference in percentage of responders between each glepaglutide treated group and placebo is tested using the Cochran-Mantel-Haenszel approach, adjusted for the stratification factor.
Improvement in the patient reported outcome, PGIC, was seen in 62.9% of patients with TW compared with 36.1% of patients with placebo. Further, improvement in PGIC was seen in 77.1% of patients with OW and the difference compared with placebo was staistically significant (CKO.0001).
Further Analysis
Further analysis of the results of the EASE SBS 1 trial revealed one technical outlier in the OW treatment arm where it was suspected at Database Lock (DBL) that the Week 20 and Week 24 PS volume data was erroneously high. This led to a re-evaluation of the trial results, leading to a further comparison in Table 5 below and Figure 3.
Table 5
Abbreviations: TW: twice weekly; OW: once weekly; N: number of patients in Full Analysis Set; Cl: confidence interval; CR: copy- reference; Ml: multiple imputation; PS: parenteral support. Notes: MMRM model includes treatment group, visit, stratification factor, treatment-by-visit interaction as factors and Baseline PS volume (L/Week) as covariate. Variance estimation is based on an unstructured covariance matrix within treatment group. Stratification factor: weekly PS volume requirements <12 L/week and >=12 L/week.
This re-evaluation did not lead to any change of the overall trial conclusion and there was a small change in the within arm PS reduction for the OW arm of the trial from baseline of 3.13 L/week to 3.76 L/week.
Conclusion
Glepaglutide treatment of SBS-CIF patients was safe, well-tolerated and resulted in improvement in clinically and patient-centric meaningful outcomes (PS needs, enteral autonomy, and PRO). The onset of effect was suprisingly early for treatment with GLP-2 analogue with a median time to clinical response of just 8 weeks with TW. There was a significant improvement in the patient reported outcome measure, PGIC, for treatment with glepaglutide both TW and OW. The population of SBS patients is considered very heterogenuous and the finding is surprising with treatment of GLP-2.
While the invention has been described in conjunction with the exemplary embodiments described above, many equivalent modifications and variations will be apparent to those skilled in the art when given this disclosure. Accordingly, the exemplary embodiments of the invention set forth are considered to be illustrative and not limiting. Various changes to the described embodiments may be made without departing from the spirit and scope of the invention. All documents cited herein are expressly incorporated by reference.
Claims
1. A glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment of a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the GLP-2 analogue is represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, the method comprises administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time, wherein the treatment results in an improvement in quality of life (QoL) of the patient.
2. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 1, wherein the improvement in quality of life (QoL) of the patient is assessed using a Patient Global Impression of Change (PGIC) status.
3. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 2, wherein the PGIC status uses a 7-point Likert Scale with responding patients reporting a much improved or very much improved status as compared to treatment with placebo.
4. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of claims 1 to 3, wherein the improved PGIC status of the patient is observable at week 24 of the treatment.
5. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of the preceding claims, wherein the treatment further comprises reducing a frequency or volume of the parenteral support received by the patient.
6. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 5, comprising reducing the frequency or volume of the parenteral support received by the patient at 12 weeks from the start of the treatment with the GLP-2 analogue, wherein the method comprises administering to the patient by subcutaneous injection 10 mg of the GLP-2 analogue twice weekly.
7. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the
treatment according to any one of the preceding claims, wherein the treatment leads to an early onset of effect, with a median time to clinical response as defined by a reduction in PS volume of at least 20% of 55 days or 8 weeks for treatment twice weekly with 10 mg glepaglutide and 161 days or 23 weeks for treatment once weekly with 10 mg glepaglutide.
8. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 6 or claim 7, wherein the patient does not require parenteral support after 24 weeks of the treatment.
9. A glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment of a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the GLP-2 analogue is represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, the method comprises administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time, wherein the treatment leads to a reduction in PS volume at 12 weeks from the start of treatment with the GLP-2 analogue.
10. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 9, wherein the treatment leads to a significant and earlier reduction in PS volume of -2.42 placebo at 12 weeks from the start of treatment with the GLP-2 analogue.
11. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of the preceding claims, wherein the method comprises administering to the patient by subcutaneous injection 10 mg of the GLP-2 analogue once weekly.
12. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of claims 1 to 10, wherein the method comprises administering to the patient by subcutaneous injection 10 mg of the GLP-2 analogue twice weekly.
13. A glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment of a human patient suffering from short bowel syndrome (SBS) and receiving parenteral support (PS), wherein the GLP-2 analogue is represented by the formula:
H-HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2, (ZP1848, SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof, the method comprises administering the GLP-2 analogue to the patient once weekly or twice weekly for a period of time, wherein the treatment leads to an early onset of effect, with a median time to clinical response as defined by a reduction in PS volume of at least 20% of 55 days or 8 weeks for treatment twice weekly with 10 mg glepaglutide and 161 days or 23 weeks for treatment once weekly with 10 mg glepaglutide.
14. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 13, the treatment further results in an improvement in quality of life (QoL) of the patient.
15. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 14, wherein the improvement in quality of life (QoL) of the patient is assessed using a Patient Global Impression of Change (PGIC) status.
16. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 15, wherein the PGIC status uses a 7-point Likert Scale with responding patients reporting a much improved or very much improved status as compared to treatment with placebo.
17. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of claims 13 to 16, wherein improved PGIC status of the patient is observable at week 24 of the treatment.
18. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of claims 13 to 17, wherein the patient does not require parenteral support after 24 weeks of the treatment.
19. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of claims 13 to 18, wherein the method comprises
administering to the patient by subcutaneous injection 10 mg of the GLP-2 analogue twice weekly.
20. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of claims 13 to 18, wherein the method comprises administering to the patient by subcutaneous injection 10 mg of the GLP-2 analogue once weekly.
21. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of the preceding claims, wherein the patient has short bowel syndrome with intestinal failure (SBS-IF) or SBS chronic IF (SBS-CIF).
22. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of the preceding claims, wherein the patient has undergone an end-jejunostomy or ileostomy, a jejuna-colic anastomosis or a jejuna-ilea- colic anastomosis.
23. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of the preceding claims, wherein the method comprises administering the GLP-2 analogue using an injection pen.
24. The glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of the preceding claims, wherein the patient receives parenteral support at an ESPEN guideline level of any one of A1 , B1 , C1 , D1 , A2, B2, C2, D2, A3, B3, C3, D3, A4, B4, C4, or D4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP23153788.7 | 2023-01-27 | ||
EP23153788 | 2023-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024156884A1 true WO2024156884A1 (en) | 2024-08-02 |
Family
ID=85132701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2024/051935 WO2024156884A1 (en) | 2023-01-27 | 2024-01-26 | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024156884A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006117565A2 (en) | 2005-05-04 | 2006-11-09 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
WO2018229252A1 (en) | 2017-06-16 | 2018-12-20 | Zealand Pharma A/S | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
WO2020065064A1 (en) | 2018-09-28 | 2020-04-02 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
WO2020065063A1 (en) | 2018-09-28 | 2020-04-02 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
-
2024
- 2024-01-26 WO PCT/EP2024/051935 patent/WO2024156884A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006117565A2 (en) | 2005-05-04 | 2006-11-09 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
WO2018229252A1 (en) | 2017-06-16 | 2018-12-20 | Zealand Pharma A/S | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
WO2020065064A1 (en) | 2018-09-28 | 2020-04-02 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
WO2020065063A1 (en) | 2018-09-28 | 2020-04-02 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
Non-Patent Citations (15)
Title |
---|
ANONYMOUS: "R&D Day - Delivering on our commitment to patients", 5 March 2021 (2021-03-05), XP055892229, Retrieved from the Internet <URL:https://az833263.vo.msecnd.net/pdf/zealand-pharma-r-and-d-day-march-2021/Zealand_Pharma_R_and_D_day_march_2021_version2.pdf> [retrieved on 20220215] * |
BENJAMIN ET AL., GUT, vol. 47, 2000, pages 112 - 119 |
BUCHMAN ALSCOLAPIO JFRYER J.: "AGA technical review on short bowel syndrome and intestinal transplantation", GASTROENTEROLOGY, vol. 124, no. 4, 2003, pages 1111 - 147 |
CHEESEMAN, AM. J. PHYSIOL., 1997, pages R1965 - 71 |
DRUCKER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, pages 7911 - 7916 |
HVISTENDAHL MARK KROGH ET AL: "Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial", vol. 44, no. 8, 5 February 2020 (2020-02-05), US, pages 1535 - 1544, XP093031072, ISSN: 0148-6071, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jpen.1767> DOI: 10.1002/jpen.1767 * |
JEPPENSEN, JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, vol. 38, no. 1, May 2014 (2014-05-01), pages 8S - 13S |
JEPPESEN ET AL., GASTROENTEROLOGY 2012, vol. 143, 2012, pages 1473 - 1481 |
JEPPESEN ET AL., GUT 2011, vol. 60, 2011, pages 902 - 914 |
NAIMI RAHIM M ET AL: "Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial", vol. 4, no. 5, 30 April 2019 (2019-04-30), pages 354 - 363, XP009513974, ISSN: 2468-1253, Retrieved from the Internet <URL:1077952576> [retrieved on 20190315], DOI: 10.1016/S2468-1253(19)30077-9 * |
PIRONI LARENDS JBOZZETTI F ET AL.: "ESPEN guidelines on chronic intestinal failure in adults", CLIN NUTR, vol. 35, no. 2, 2016, pages 247 - 307, XP029447113, DOI: 10.1016/j.clnu.2016.01.020 |
PIRONI LARENDS JBOZZETTI F ET AL.: "ESPEN guidelines on chronic intestinal failure in adults", CLIN. NUTR., vol. 35, no. 2, 2016, pages 247 - 307, XP029447113, DOI: 10.1016/j.clnu.2016.01.020 |
SCHWARTZ ET AL., CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, vol. 7, 2016, pages e142 |
WOJDEMANN ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 84, 1999, pages 2513 - 2517 |
ZEALAND PHARMA: "Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS - Tabular View - ClinicalTrials.gov", 31 October 2022 (2022-10-31), XP093031069, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT03690206?term=NCT03690206&draw=2&rank=1> * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210363263A1 (en) | Myostatin, activin or activin receptor antagonists for use in treating obesity and related conditions | |
US11738086B2 (en) | Methods of using buffered formulations of exendin (9-39) | |
US11622995B2 (en) | Treatment of post-bariatric hypoglycemia with GLP-1 antagonists | |
JP6005140B2 (en) | Combination medicine for use in the treatment of patients with type 2 diabetes | |
Zambrowicz et al. | LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion | |
JP2008518941A (en) | Treatment of patients with short bowel syndrome with colorectal continuity | |
JP2019535734A5 (en) | ||
KR20180051560A (en) | Co-therapy including cannabis glyphogens and pentamers for the treatment of obesity and obesity-related disorders | |
BR112013014642A2 (en) | pharmaceutical product, kit, use, products, methods and innovative uses | |
EP4025248A1 (en) | Treatment of liver disease or disorder comprising actrii receptor antagonists | |
WO2024156884A1 (en) | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) | |
US20240002490A1 (en) | Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy | |
TW202323296A (en) | Combination therapies | |
CA3202157A1 (en) | Use of glp-2 analogues in patients with renal insufficiency | |
Oke et al. | British Intestinal Failure Alliance (BIFA) Position Statement Use of peptide growth factors for adult patients with intestinal failure | |
WO2024068933A1 (en) | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) | |
WO2023235724A1 (en) | Methods of using a gcg/glp1 co-agonist for therapy | |
TWI848773B (en) | Methods of treating obesity, overweight condition, central adiposity and related comorbidities by improving body composition | |
TW202417035A (en) | Tirzepatide compositions and use | |
WO2024059480A2 (en) | A gip/glp1 for use in therapy | |
TW202140061A (en) | Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes | |
Scolapio et al. | 19 Glucagon-Like Peptide-2 in Short Bowel Syndrome | |
Scolapio et al. | 19 Glucagon-Like Peptide-2 | |
Oke et al. | British Intestinal Failure Alliance (BIFA) Position Statement Use of GLP-2 analogues and other growth factors for adult patients with intestinal failure | |
TW201311268A (en) | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |